Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Group 1 - Spero Therapeutics has decided to stop its PIVOT-PO Phase 3 trial early, following the recommendation of the IDMC [1] - The trial's objective of non-inferiority to intravenous imipenem-cilastatin was achieved [1]